Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects
Summary Rituximab is a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B-cell lymphoma. It is widely used as single agent for the treatment of follicular lymphoma or in conjunction with other combination therapy as frontline or salvage therapy. Its efficiency in B-c...
Gespeichert in:
Veröffentlicht in: | Cancer treatment reviews 2009-12, Vol.35 (8), p.653-661 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 661 |
---|---|
container_issue | 8 |
container_start_page | 653 |
container_title | Cancer treatment reviews |
container_volume | 35 |
creator | Ratanatharathorn, Voravit Pavletic, Steven Uberti, Joseph P |
description | Summary Rituximab is a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B-cell lymphoma. It is widely used as single agent for the treatment of follicular lymphoma or in conjunction with other combination therapy as frontline or salvage therapy. Its efficiency in B-cell depletion has lead to other applications such as therapy for autoimmune diseases, GVHD and other immunologic complications in allogeneic stem cell transplantation. Clinical responses to rituximab unveiled the role of B-cells in the pathogenesis of these disorders. Attenuation of pathogenic antibody production partly explained the clinical response in patients with autoimmune disease and chronic GVHD, but other immune mechanisms might be operative as well. Expansion of regulatory T-cells (Tregs) following rituximab therapy indicated the interaction of T- and B-cells in chronic GVHD. Therefore, effort to maintain expansion of Tregs might be important for long-term control of these diseases. Other B-cell targeting strategy directing against B-cell-activating factor (BAFF) or its receptor could be considered in conjunction with rituximab. Recent CIBMTR data on reduced cumulative incidence of acute GVHD in patients who had prior rituximab also suggest the early role of B-cells in allogeneic transplantation, thus opening the opportunity for further immune modulation to prevent acute GVHD. |
doi_str_mv | 10.1016/j.ctrv.2009.07.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734158152</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030573720900111X</els_id><sourcerecordid>21324657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-cd6e5a6e7f229151e42dc7b78daa304656f7fd2d19e7b9d87a82c7e460f3a6e03</originalsourceid><addsrcrecordid>eNp9klGL1DAUhYMo7uzqH_BB8qRPHW-StmlFFpbBVWHBBxV8C5nkVjK2SU3Sxfn3ps6A4MM-JZDvnFzOuYS8YLBlwNo3h63J8X7LAfotyC1A_YhsWCN4xfpWPiYbENBUUkh-QS5TOkABRds_JRflveMdsA1Ju9F5Z_RI9TyP5ZJd8ImGgUaXl99u0nvqPNXjGH6gR2doyjhRg-NIc9Q-zaP2-a_qLb3x2VV5mUKk2lvqpmnxYQp2GXUO8UhxGNDk9Iw8GfSY8Pn5vCLfbt9_3X2s7j5_-LS7uatMAzJXxrbY6BblwHnPGoY1t0buZWe1FlC3TTvIwXLLepT73nZSd9xIrFsYRJGBuCKvT75zDL8WTFlNLq2Ta49hSUqKmjUda3ghXz1IciZ4-VAWkJ9AE0NKEQc1x5JRPCoGai1FHdRailpLUSBVKaWIXp7dl_2E9p_k3EIB3p0ALGncO4wqGYfeoHWxBKZscA_7X_8nN-dSf-IR0yEs0ZecFVOJK1Bf1rVYtwJ6AMbYd_EHBXq1hw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21324657</pqid></control><display><type>article</type><title>Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ratanatharathorn, Voravit ; Pavletic, Steven ; Uberti, Joseph P</creator><creatorcontrib>Ratanatharathorn, Voravit ; Pavletic, Steven ; Uberti, Joseph P</creatorcontrib><description>Summary Rituximab is a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B-cell lymphoma. It is widely used as single agent for the treatment of follicular lymphoma or in conjunction with other combination therapy as frontline or salvage therapy. Its efficiency in B-cell depletion has lead to other applications such as therapy for autoimmune diseases, GVHD and other immunologic complications in allogeneic stem cell transplantation. Clinical responses to rituximab unveiled the role of B-cells in the pathogenesis of these disorders. Attenuation of pathogenic antibody production partly explained the clinical response in patients with autoimmune disease and chronic GVHD, but other immune mechanisms might be operative as well. Expansion of regulatory T-cells (Tregs) following rituximab therapy indicated the interaction of T- and B-cells in chronic GVHD. Therefore, effort to maintain expansion of Tregs might be important for long-term control of these diseases. Other B-cell targeting strategy directing against B-cell-activating factor (BAFF) or its receptor could be considered in conjunction with rituximab. Recent CIBMTR data on reduced cumulative incidence of acute GVHD in patients who had prior rituximab also suggest the early role of B-cells in allogeneic transplantation, thus opening the opportunity for further immune modulation to prevent acute GVHD.</description><identifier>ISSN: 0305-7372</identifier><identifier>EISSN: 1532-1967</identifier><identifier>DOI: 10.1016/j.ctrv.2009.07.004</identifier><identifier>PMID: 19682801</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acute Disease ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Agents - immunology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - immunology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B-cells APC ; B-cells in transplantation ; B-Lymphocytes - drug effects ; B-Lymphocytes - immunology ; BMT ; Chemokines - immunology ; Chronic Disease ; Cytokines - immunology ; Graft vs Host Disease - complications ; Graft vs Host Disease - immunology ; Graft vs Host Disease - prevention & control ; GVHD ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, B-Cell - drug therapy ; Lymphoma, B-Cell - immunology ; Rituximab ; Rituximab manuscript ; T-Lymphocytes - immunology ; Thrombocytopenia - immunology ; Transplantation Conditioning ; Transplantation, Homologous</subject><ispartof>Cancer treatment reviews, 2009-12, Vol.35 (8), p.653-661</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-cd6e5a6e7f229151e42dc7b78daa304656f7fd2d19e7b9d87a82c7e460f3a6e03</citedby><cites>FETCH-LOGICAL-c507t-cd6e5a6e7f229151e42dc7b78daa304656f7fd2d19e7b9d87a82c7e460f3a6e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S030573720900111X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19682801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ratanatharathorn, Voravit</creatorcontrib><creatorcontrib>Pavletic, Steven</creatorcontrib><creatorcontrib>Uberti, Joseph P</creatorcontrib><title>Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects</title><title>Cancer treatment reviews</title><addtitle>Cancer Treat Rev</addtitle><description>Summary Rituximab is a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B-cell lymphoma. It is widely used as single agent for the treatment of follicular lymphoma or in conjunction with other combination therapy as frontline or salvage therapy. Its efficiency in B-cell depletion has lead to other applications such as therapy for autoimmune diseases, GVHD and other immunologic complications in allogeneic stem cell transplantation. Clinical responses to rituximab unveiled the role of B-cells in the pathogenesis of these disorders. Attenuation of pathogenic antibody production partly explained the clinical response in patients with autoimmune disease and chronic GVHD, but other immune mechanisms might be operative as well. Expansion of regulatory T-cells (Tregs) following rituximab therapy indicated the interaction of T- and B-cells in chronic GVHD. Therefore, effort to maintain expansion of Tregs might be important for long-term control of these diseases. Other B-cell targeting strategy directing against B-cell-activating factor (BAFF) or its receptor could be considered in conjunction with rituximab. Recent CIBMTR data on reduced cumulative incidence of acute GVHD in patients who had prior rituximab also suggest the early role of B-cells in allogeneic transplantation, thus opening the opportunity for further immune modulation to prevent acute GVHD.</description><subject>Acute Disease</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antineoplastic Agents - immunology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - immunology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B-cells APC</subject><subject>B-cells in transplantation</subject><subject>B-Lymphocytes - drug effects</subject><subject>B-Lymphocytes - immunology</subject><subject>BMT</subject><subject>Chemokines - immunology</subject><subject>Chronic Disease</subject><subject>Cytokines - immunology</subject><subject>Graft vs Host Disease - complications</subject><subject>Graft vs Host Disease - immunology</subject><subject>Graft vs Host Disease - prevention & control</subject><subject>GVHD</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Lymphoma, B-Cell - immunology</subject><subject>Rituximab</subject><subject>Rituximab manuscript</subject><subject>T-Lymphocytes - immunology</subject><subject>Thrombocytopenia - immunology</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Homologous</subject><issn>0305-7372</issn><issn>1532-1967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9klGL1DAUhYMo7uzqH_BB8qRPHW-StmlFFpbBVWHBBxV8C5nkVjK2SU3Sxfn3ps6A4MM-JZDvnFzOuYS8YLBlwNo3h63J8X7LAfotyC1A_YhsWCN4xfpWPiYbENBUUkh-QS5TOkABRds_JRflveMdsA1Ju9F5Z_RI9TyP5ZJd8ImGgUaXl99u0nvqPNXjGH6gR2doyjhRg-NIc9Q-zaP2-a_qLb3x2VV5mUKk2lvqpmnxYQp2GXUO8UhxGNDk9Iw8GfSY8Pn5vCLfbt9_3X2s7j5_-LS7uatMAzJXxrbY6BblwHnPGoY1t0buZWe1FlC3TTvIwXLLepT73nZSd9xIrFsYRJGBuCKvT75zDL8WTFlNLq2Ta49hSUqKmjUda3ghXz1IciZ4-VAWkJ9AE0NKEQc1x5JRPCoGai1FHdRailpLUSBVKaWIXp7dl_2E9p_k3EIB3p0ALGncO4wqGYfeoHWxBKZscA_7X_8nN-dSf-IR0yEs0ZecFVOJK1Bf1rVYtwJ6AMbYd_EHBXq1hw</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Ratanatharathorn, Voravit</creator><creator>Pavletic, Steven</creator><creator>Uberti, Joseph P</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects</title><author>Ratanatharathorn, Voravit ; Pavletic, Steven ; Uberti, Joseph P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-cd6e5a6e7f229151e42dc7b78daa304656f7fd2d19e7b9d87a82c7e460f3a6e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acute Disease</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antineoplastic Agents - immunology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - immunology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B-cells APC</topic><topic>B-cells in transplantation</topic><topic>B-Lymphocytes - drug effects</topic><topic>B-Lymphocytes - immunology</topic><topic>BMT</topic><topic>Chemokines - immunology</topic><topic>Chronic Disease</topic><topic>Cytokines - immunology</topic><topic>Graft vs Host Disease - complications</topic><topic>Graft vs Host Disease - immunology</topic><topic>Graft vs Host Disease - prevention & control</topic><topic>GVHD</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Lymphoma, B-Cell - immunology</topic><topic>Rituximab</topic><topic>Rituximab manuscript</topic><topic>T-Lymphocytes - immunology</topic><topic>Thrombocytopenia - immunology</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ratanatharathorn, Voravit</creatorcontrib><creatorcontrib>Pavletic, Steven</creatorcontrib><creatorcontrib>Uberti, Joseph P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer treatment reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ratanatharathorn, Voravit</au><au>Pavletic, Steven</au><au>Uberti, Joseph P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects</atitle><jtitle>Cancer treatment reviews</jtitle><addtitle>Cancer Treat Rev</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>35</volume><issue>8</issue><spage>653</spage><epage>661</epage><pages>653-661</pages><issn>0305-7372</issn><eissn>1532-1967</eissn><abstract>Summary Rituximab is a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B-cell lymphoma. It is widely used as single agent for the treatment of follicular lymphoma or in conjunction with other combination therapy as frontline or salvage therapy. Its efficiency in B-cell depletion has lead to other applications such as therapy for autoimmune diseases, GVHD and other immunologic complications in allogeneic stem cell transplantation. Clinical responses to rituximab unveiled the role of B-cells in the pathogenesis of these disorders. Attenuation of pathogenic antibody production partly explained the clinical response in patients with autoimmune disease and chronic GVHD, but other immune mechanisms might be operative as well. Expansion of regulatory T-cells (Tregs) following rituximab therapy indicated the interaction of T- and B-cells in chronic GVHD. Therefore, effort to maintain expansion of Tregs might be important for long-term control of these diseases. Other B-cell targeting strategy directing against B-cell-activating factor (BAFF) or its receptor could be considered in conjunction with rituximab. Recent CIBMTR data on reduced cumulative incidence of acute GVHD in patients who had prior rituximab also suggest the early role of B-cells in allogeneic transplantation, thus opening the opportunity for further immune modulation to prevent acute GVHD.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>19682801</pmid><doi>10.1016/j.ctrv.2009.07.004</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-7372 |
ispartof | Cancer treatment reviews, 2009-12, Vol.35 (8), p.653-661 |
issn | 0305-7372 1532-1967 |
language | eng |
recordid | cdi_proquest_miscellaneous_734158152 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Acute Disease Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents - immunology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - immunology Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-cells APC B-cells in transplantation B-Lymphocytes - drug effects B-Lymphocytes - immunology BMT Chemokines - immunology Chronic Disease Cytokines - immunology Graft vs Host Disease - complications Graft vs Host Disease - immunology Graft vs Host Disease - prevention & control GVHD Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation Humans Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - immunology Rituximab Rituximab manuscript T-Lymphocytes - immunology Thrombocytopenia - immunology Transplantation Conditioning Transplantation, Homologous |
title | Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A26%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20applications%20of%20rituximab%20in%20allogeneic%20stem%20cell%20transplantation:%20Anti-tumor%20and%20immunomodulatory%20effects&rft.jtitle=Cancer%20treatment%20reviews&rft.au=Ratanatharathorn,%20Voravit&rft.date=2009-12-01&rft.volume=35&rft.issue=8&rft.spage=653&rft.epage=661&rft.pages=653-661&rft.issn=0305-7372&rft.eissn=1532-1967&rft_id=info:doi/10.1016/j.ctrv.2009.07.004&rft_dat=%3Cproquest_cross%3E21324657%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21324657&rft_id=info:pmid/19682801&rft_els_id=S030573720900111X&rfr_iscdi=true |